Concentrate-related inhibitor risk: is a difference always real?

Free article

Comment

A Iorio et al. J Thromb Haemost. 2011 Nov.

Free article

. 2011 Nov;9(11):2176-9.

doi: 10.1111/j.1538-7836.2011.04480.x.

No abstract available

Comment in

Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.
Aledort LM, Navickis RJ, Wilkes MM. Aledort LM, et al. J Thromb Haemost. 2011 Nov;9(11):2325-7. doi: 10.1111/j.1538-7836.2011.04496.x. J Thromb Haemost. 2011. PMID: 21880112 No abstract available.
Factor VIII inhibitors in previously treated hemophilic patients.
Mannucci PM. Mannucci PM. J Thromb Haemost. 2011 Nov;9(11):2328-9. doi: 10.1111/j.1538-7836.2011.04510.x. J Thromb Haemost. 2011. PMID: 21929691 No abstract available.

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.
Kempton CL, Soucie JM, Abshire TC. Kempton CL, et al. J Thromb Haemost. 2006 Dec;4(12):2576-81. doi: 10.1111/j.1538-7836.2006.02233.x. Epub 2006 Sep 26. J Thromb Haemost. 2006. PMID: 17002659
Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment.
Aledort LM. Aledort LM. J Thromb Haemost. 2011 Mar;9(3):423-7. doi: 10.1111/j.1538-7836.2010.04169.x. J Thromb Haemost. 2011. PMID: 21143382 Review.